Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Undersökning av hjärnmekanismer involverade i urinkontinensmekanismen associerad med åldrande

1 oktober 2026 uppdaterad av: Becky Clarkson, University of Pittsburgh

Urge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of better treatment.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Current data suggest that bladder control comprises 3 cerebral circuits that maintain continence by suppressing the voiding reflex in the midbrain. In the UUI phenotype that responded to BFB (Biofeedback assisted pelvic floor muscle therapy), the mechanism involved enhancing deactivation of the first brain circuit (medial prefrontal cortex, mPFC) which resulted in less activation of the second circuit (which includes the midcingulate cortex). In the phenotype that was resistant to BFB, no brain changes were seen. Although the investigators have an emerging picture of the brain's role in UUI, the investigators have only rudimentary understanding of what is 'normal', i.e. how the brain normally controls the bladder. Moreover, the investigators do not know whether this control mechanism is the same across the lifespan, or whether it changes owing to the impact of aging. Thus, the investigators aims are to characterize the brain's normal role in bladder control in both young and old people, to determine the changes in brain structure and function that lead to bladder control failure (UUI), and to examine how such changes differ between young and old individuals. To address the aims, the investigators will utilize detailed neuroimaging to evaluate 80 asymptomatic women and 80 women with UUI, each group divided into young (18-45) and old (65+ years) individuals. The study will enable the investigators to define the brain's key structures, functional activity, and mechanisms involved in normal bladder control, and to identify the differences in these elements among those with UUI, both young and old.

By elucidating the mechanisms that mediate the brain's control (and loss of control) of bladder function, the proposed study should enhance the investigators working model, deepen the understanding of the impact of aging, and identify better targets for the treatment of UUI. It may thereby enable scientists to develop novel and more effective new therapies based on the revolution in neuroscience-and more hope for UUI sufferers.

Studietyp

Interventionell

Inskrivning (Faktisk)

217

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • University of Pittsburgh

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • 'Old' (community-dwelling, mentally and functionally intact ambulatory women aged 65+ years) or 'Young' (equivalent women aged 18-45)
  • 'Wet' (those who meet the International Continence Society definition of urgency urinary incontinence (urinary leakage accompanied by a sudden, strong urge to void which is difficult to defer) >5 times per week, for 3 months despite treatment for reversible causes (e.g., Urinary tract infection) and confirmed by a mean of one episode per day of UUI on 3-day bladder diary) or 'Dry' (women without current or past UUI or other lower urinary tract symptoms.) Infrequent stress incontinence of a small amount is acceptable.
  • Urge-predominant mixed incontinence is acceptable provided the subject is able to differentiate between stress incontinence (SUI - leakage that coincides instantaneously with cough, laugh, exercise) and urgency incontinence, i.e., leakage accompanied by a sudden strong urge to void that is difficult to defer.
  • Those with current or previous use of anticholinergic/beta-3 agonist medications will be considered for the study if they are willing to go through a washout period of at least 4 weeks of duration.

Exclusion Criteria:

Dry Groups

  • Current or prior treatment for UUI
  • Leakage on bladder diary not ascribed to minimal SUI (see bullet above)

All Groups: 'Wet' or 'Dry'; 'Young' or 'Old'

  • Cognitive impairment:

    • MoCA<26
    • inability to perform a voiding diary/pad test
    • inability to reliably take daily medication
    • inability to comply with fMRI testing
  • Impaired mobility

    o Timed up and go test ≥ 12 secs

  • Medical instability:

    • severe uncontrolled hypertension >180mmHg systolic or >100mmHg diastolic
    • potential major changes in medical management over the course of the study period (i.e. upcoming surgery/treatment)
    • frailty according to the Fried criteria
  • MRI incompatibility:

    • contraindicated metal implants
    • claustrophobia
    • unidentified/untested compatibility of metal implants
  • Medication incompatibility:

    • allergy to study medication (all prophylactic antibiotic choices)
    • interaction of prophylactic antibiotic choices with current medications
    • expected change in medication during the study
  • Neurological conditions:

    • spinal cord injury;
    • multiple sclerosis
    • clinically apparent lesions (e.g. lacunae associated with stroke)
    • prior stroke
    • Parkinson's Disease/ALS/MSA
    • any clinically apparent neurological condition
  • Lower urinary tract comorbidities/treatment:

    • history of pelvic irradiation
    • bladder or advanced uterine cancer
    • possible urethral obstruction (advanced prolapse [POP-Q>II] or Qmax<12 ml/s on free flow)
    • urinary retention (PVR >200 ml)
    • Interstitial Cystitis/Bladder Pain Syndrome
    • artificial sphincter implant
    • Botox treatment for UUI within 1 year
    • Neuromodulation treatment for UUI
  • Other comorbidities:

    • uncontrolled depression (PHQ-9 ≥10)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Brain functional MRI with simplified urodynamics

Females with urgency urinary incontinence

Structural:

MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.

Functional:

With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC
Tidsram: Baseline

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit.

The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Baseline
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula
Tidsram: Baseline

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit.

The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Baseline
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC
Tidsram: Baseline

BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit.

The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.

Baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Utredare

  • Huvudutredare: Becky Clarkson, PhD, University of Pittsburgh

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 december 2020

Primärt slutförande (Faktisk)

31 juli 2025

Avslutad studie (Faktisk)

1 april 2026

Studieregistreringsdatum

Först inskickad

1 oktober 2020

Först inskickad som uppfyllde QC-kriterierna

21 oktober 2020

Första postat (Faktisk)

22 oktober 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • STUDY20080217
  • R01AG065288 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All of the individual participant data collected during the trial, after de-identification may be shared with other researchers.

Tidsram för IPD-delning

Following publication, no end date

Kriterier för IPD Sharing Access

Any purpose

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .